Federal Health & Wellness
New Organ-Procurement Rule Raises the Bar for Safety and Competition
Federal standards add adverse-event reporting, medical oversight and a path for high-performing organizations to compete.
The rule's purpose
The Centers for Medicare & Medicaid Services announced a final rule October 30 governing organ procurement organizations, the regional nonprofits that coordinate recovery of donated organs. CMS says more than 49,000 transplants occurred in 2025 while more than 100,000 people remained on the waiting list. Those figures frame a system in which both missed donation opportunities and unsafe practices can have severe consequences. The rule changes certification and oversight; it does not itself allocate an organ to an individual patient.
Competition and recertification
Under the final rule, high-performing procurement organizations may compete to serve more than one donation service area. CMS presents that change as a way to strengthen accountability when an organization fails performance standards. Competition, however, still requires an orderly transition: hospitals, donor families, laboratories, transport providers and transplant programs depend on continuous coordination. The agency's implementation materials and future recertification decisions will show how performance data translates into an actual service-area change.
Safety controls become more explicit
CMS says the rule adds requirements for reporting adverse events and permits decertification for unsafe practices. It also strengthens documentation and medical-director standards, including licensure expectations. These provisions matter because speed cannot replace traceability. A recovery decision should be supported by records showing what was known, which tests were completed, how an organ was handled and who exercised clinical authority. Adverse-event reporting can reveal patterns only if reports are timely, comparable and followed by corrective review.
Research organs and chain of custody
The final rule addresses pancreases recovered for research, an area where performance incentives and documentation have drawn scrutiny. Clear records should distinguish an organ intended for transplant from one directed to research and explain the basis for the classification. That does not mean research recovery is improper; it means each pathway needs its own verifiable purpose and custody record. Future audit results will be more informative than broad claims about how often a category was used.
What patients should understand
The national waiting list is managed through rules and clinical criteria beyond this one regulation. Patients should continue to work with their transplant center for case-specific information rather than interpret the final rule as a change in their individual position. The most important public follow-up will be implementation dates, performance reports, enforcement actions and any service-area transitions. This article summarizes CMS's final action without promising that the rule will immediately increase transplants or eliminate every safety risk.
Primary evidence
Reporting note: This independently composed article is based on the linked primary records. Publication and event dates are stated separately. Agency claims are identified as such; an allegation, charge or scheduled event is not presented as a finding, conviction or completed event. Readers should consult the official record for amendments and later action.